Try

Damora Therapeutics, Inc.

DMRAUnited States

21 filed reports · 238 financial concepts · 0 earnings calls · 0 media appearances

Filed reports

21 reports · Jun 2021 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR161,905Jun 2021 to Jun 2026
Annual · 10-KSEC EDGAR51,377Dec 2021 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q210-QJun 30, 2026Aug 10, 2026220Open
FY2026 Q110-QMar 31, 2026May 12, 2026142Open
FY202510-KDec 31, 2025Mar 19, 2026425Open
FY2025 Q310-QSep 30, 2025Nov 6, 2025154Open
FY2025 Q210-QJun 30, 2025Aug 5, 2025109Open
FY2025 Q110-QMar 31, 2025May 8, 2025109Open
FY202410-KDec 31, 2024Mar 19, 2025259Open
FY2024 Q310-QSep 30, 2024Nov 1, 2024117Open
FY2024 Q210-QJun 30, 2024Aug 12, 2024105Open
FY2024 Q110-QMar 31, 2024Apr 29, 2024109Open
FY202310-KDec 31, 2023Mar 8, 2024254Open
FY2023 Q310-QSep 30, 2023Nov 6, 2023110Open

Financial data

238 concepts · 3,282 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial237 concepts · 3,280 facts · Mar 2020 to Jun 2026

  • Contract research and development costs61 · Dec 2020 to Jun 2026
  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value31 · Jun 2020 to Jun 2026
  • Allocated share based compensation expense31 · Jun 2020 to Jun 2026
  • Cash and cash equivalents at carrying value31 · Jun 2020 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents31 · Jun 2020 to Jun 2026
  • Comprehensive income net of tax31 · Jun 2020 to Jun 2026
  • Foreign currency transaction gain loss before tax31 · Jun 2020 to Jun 2026
  • General and administrative expense (US GAAP)31 · Jun 2020 to Jun 2026
  • Net income loss31 · Jun 2020 to Jun 2026
  • Nonoperating income expense31 · Jun 2020 to Jun 2026
  • Operating expenses (US GAAP)31 · Jun 2020 to Jun 2026
  • Operating income loss31 · Jun 2020 to Jun 2026
  • Other comprehensive income loss foreign currency transaction and translation adjustment net of tax31 · Jun 2020 to Jun 2026
  • Other comprehensive income loss net of tax portion attributable to parent31 · Jun 2020 to Jun 2026
  • Profit loss31 · Jun 2020 to Jun 2026
  • Research and development expense31 · Jun 2020 to Jun 2026
  • Stockholders equity (US GAAP)31 · Jun 2020 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect30 · Sep 2020 to Jun 2026
  • Effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents30 · Sep 2020 to Jun 2026
  • Increase decrease in accounts payable30 · Sep 2020 to Jun 2026
  • Increase decrease in accrued liabilities and other operating liabilities30 · Sep 2020 to Jun 2026
  • Increase decrease in prepaid deferred expense and other assets30 · Sep 2020 to Jun 2026
  • Net cash provided by used in operating activities30 · Sep 2020 to Jun 2026
  • Operating lease right of use asset amortization expense30 · Sep 2020 to Jun 2026

Geography1 concepts · 2 facts · Jun 2024 to Sep 2024

  • Income tax expense benefit2 · Jun 2024 to Sep 2024

Segments

2 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement geographical1 member · 2 facts

  • GB2 · Jun 2024 to Sep 2024

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.

Damora Therapeutics, Inc. (DMRA) data · FactIQ